Emergent BioSolutions (EBS) Reports Q1 Loss of $3.17
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.58 +0.66%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
(Updated - May 9, 2023 5:00 PM EDT)
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of ($3.17), versus $0.00 reported last year. Revenue for the quarter came in at $165.1 million versus the consensus estimate of $175.12 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- Azitra, Inc. (AZTR) Tops Q2 EPS by 54c
- Axos Financial (AX) PT Raised to $120 at Benchmark
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
